EGFR and neoplasm: While anti-EGFR treatments target the EGFR pathway to inhibit tumor growth, NRAS mutations can activate downstream signaling pathways independently of EGFR, allowing tumor cells to evade EGFR blockade and continue proliferating [25, 26].